Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial - Top-Institutions - MDSpire

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

  • By

  • Thierry Lebret

  • Xavier Paoletti

  • Geraldine Pignot

  • Mathieu Roumiguié

  • Marc Colombel

  • Laurent Savareux

  • Grégory Verhoest

  • Laurent Guy

  • Jérome Rigaud

  • Stéphane De Vergie

  • Grégoire Poinas

  • Stéphane Droupy

  • François Kleinclauss

  • Monique Courtade-Saïdi

  • Eric Piaton

  • Camelia Radulescu

  • Nathalie Rioux-Leclercq

  • Christine Kandel-Aznar

  • Karine Renaudin

  • Béatrix Cochand-Priollet

  • Yves Allory

  • Sébastien Nivet

  • Morgan Rouprêt

  • July 22, 2023

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Pathology
    • Artificial Intelligence in Medicine

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Pathology
    • Biomedical Informatics

  • #3

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology
    • Urology
    • Artificial Intelligence in Cancer Diagnostics

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Urology
    • Pathology
    • Computational Medicine

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Urology
    • Pathology
    • Biomedical Data Science

Original Source(s)

Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial

  • by Thierry Lebret, Xavier Paoletti, Geraldine Pignot, Mathieu Roumiguié, Marc Colombel, Laurent Savareux, Grégory Verhoest, Laurent Guy, Jérome Rigaud, Stéphane De Vergie, Grégoire Poinas, Stéphane Droupy, François Kleinclauss, Monique Courtade-Saïdi, Eric Piaton, Camelia Radulescu, Nathalie Rioux-Leclercq, Christine Kandel-Aznar, Karine Renaudin, Béatrix Cochand-Priollet, Yves Allory, Sébastien Nivet, Morgan Rouprêt

  • July 22, 2023

Related Content

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions

Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA

Novel contrast-enhanced ultrasound imaging in prostate cancer